Diagnostics Division Daniel O Day COO Roche Diagnostics
|
|
- Jeffry Thomas
- 6 years ago
- Views:
Transcription
1 Diagnostics Division Daniel O Day COO Roche Diagnostics 1
2 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates, future or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage. Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche. For marketed products discussed in this presentation, please see full prescribing information on our website All mentioned trademarks are legally protected 2
3 Q1 2010: High growth for both divisions Well above world markets CHF bn % change in Q1 09 Q1 10 CHF local harmaceuticals Diagnostics Roche Group
4 Diagnostics Division Continues to grow significantly above the IVD market Q1 09 Q1 10 CHF local CHF m CHF m growth growth rofessional Diagnostics 1,086 1,170 8% 9% Diabetes Care % 6% Molecular Diagnostics % 2% Applied Science % 19% Tissue Diagnostics % 21% Diagnostics Division 2,361 2,518 7% 9% IVD = in vitro diagnostics 4
5 Roche Diagnostics strategy firmly on track Accessing novel content is a key driver of differentiation Improving Medical Value Expanding menu Novel markers Companion Dx Increasing Testing Efficiency Automation Workflow IT
6 Innovative product launches - on both fronts Expand leadership, develop new markets, drive growth cobas 8000 Consolidated clinical chemistry & immunoassays Accu-Chek Mobile Integrated blood glucose meter Testing efficiency cobas 4800 Automated CR Benchmark Ultra Automated IHC & ISH LightCycler 1536 High throughput CR Medical value Trop I, hstrop T, IL-6, anti-cc, lgf/ SFlt1, tsa, fsa Strip-free meter (Mobile) Combined pump & meter (Combo) HV, CT/NG KRAS Mutations HER2 SISH & Gastric, MET, EGFR 17 Oncology Antibodies Influenza A/H1N1 Sequencing reagents 6
7 Increasing testing efficiency Strong launch cobas 8000 modular analyzer series H Q2 Q3 Q4 hase 1a: Very high volume laboratories c 701 c 502 EMEA AAC (AUS, NZ, HK) US hase 1b: Very high volume laboratories e 602 EMEA AAC (AUS, NZ, HK) US c 702 e 602 hase 2: High vol laboratories EMEA All AAC LATAM c = clinical chemistry modules e = Immunoassay modules 7
8 Accu-Chek meters and pumps Continued roll-out of innovative products driving growth 2008 Accu-Chek Aviva Nano 2009 Accu-Chek Mobile Accu-Chek erforma Nano Small, sleek design developed for young, high-frequency testers Successful competitor conversions Accu-chek Aviva Nano US launch H2 Only strip-free system enabling less steps for greater ease of use Available in 12 countries in EU & AAC Accu-Chek Combo First interactive insulin pump in EU allowing patients to operate pump by meter Now launched in 16 markets 8
9 The unique Medingo patch-pump technology Lower hurdles for patients to switch to pump therapy Insulin delivery market ~CHF 1.6 bn, growing at +11% Insulin patch pump segment estimated to grow over-proportionally atients new to pumps in the U.S. increasingly favor patch-pump systems Current durable pumps hurdles: weight, size, infusion set high initial up-front costs Source: Boston Medical Consultants, Company Reports, Roche Analysis Bolus buttons Adhesive Cannula Micro patch-pump: light weight, tubing-free Competitive advantages: semi-disposable product solution - easy disconnect & reconnect function direct bolus release on pump Significantly lower up-front costs for patient Launch planned for
10 Creating medical value Through new diagnostics tests Medical Value Diagnostics Screening Diagnosis rognosis rediction Monitoring Companion Diagnostics + Treatment selection Response prediction Treatment monitoring 10
11 Cervical Cancer: HV screening algorithms Growth and market size driven by adoption of screening Clinical Applications Number of HV tests in the US ASCUS Triage Adjunct screening + + ap HV Colposcopy ap/ HV - 1 year year 3 years Colposcopy ~1 m U.S. Market: $250 m, 20% growth per year ~28 m rimary screening HV + + ap - 3 years Colposcopy ~50 m Company reports, Roche analysis 11
12 ATHENA trial demonstrates medical value of HV testing and Genotyping in Cervical Cancer screening Enrolment Completed 2009 ~47,000 women The ATHENA Trial Women with colposcopy (~8,000) Follow-Up Year 1 Follow-Up Year 2 Cytology vs. HV Testing* Follow-Up Year 3 Targets ASCUS triage, adjunct screening and HV 16/18 claims Study results confirm variability of cytology and support improved consistency of HV DNA based cervical cancer screening programs Site Cytology Abnormal CIN 2+ overall A 3.7% 6.5% B 5.2% 6.1% C 8.1% 5.7% D 9.8% 4.5% Data support HV 16/18 genotyping as actionable information for intervention HR HV ositive Deferred follow up ASCUS/ HV- 13.8% Yearly follow up * Wright, TC., EUROGIN % 15.6% Immediate follow up ASCUS/ HV+ 15.5% Immediate follow up for HV 16/18 ap-/ HV - ap-/ HV + ap-/ 16/18+ ASCUS/ 16/18+ 2 % 10 % Increasing risk of CIN2+ FDA submission mid 2010; data to be presented at IV, Montreal 07/2010 ATHENA establishes the value of genotyping in cervical cancer screening programs 12
13 rostate Cancer: Rearrangements between TMRSS2 and ERG genes found in ~50% of prostate cancer patients Survival from rostate Cancer % Overall survival from rostate cancer* 5 Deletion/ 3 Duplication Normal 70%, n=311 5 Deletion Rearrangement status may determine clinical outcome How aggressive is my cancer? What should the course of my primary therapy be? What is my risk of metastasis? * Oncogene (2008) 27, TMRSS2= transmembrane protease, serine 2 (androgen responsive gene) ERG=Ets Related Gene 13
14 Assay in development for ERG gene rearrangements Identifying prostate cancer aggressiveness for appropriate treatment Oncologist Surgeon atient tumor needle biopsy Imaged Slide Review for athologist Normal Likely Indolent 3 Insertion Likely Aggressive Ventana SYMHONY rostate cancer diagnosis via H&E 5 Deletion Likely Aggressive Ventana BenchMark ULTRA 5 Deletion and 3 Duplication Highly Aggressive 14
15 Creating medical value Through Companion Diagnostics Medical Value Diagnostics Screening Diagnosis rognosis rediction Monitoring Companion Diagnostics + Treatment selection Response prediction Treatment monitoring 15
16 Strong pipeline of companion diagnostics Joint harma and Diagnostics programs - Oncology Roche harma targeting multiple pathways Molecular Tests for assessing presence of mutations offers opportunities to tailor treatment RTK ipeline Drug Biomarker ipeline Assay Ras Ras p110a I I 22 p85 p85 I I 33 TEN RG7204 BRAF Inh/LX4032 RG7167 MEK Inh/CIF RG7112 MDM2 Antagonist RG7112 MDM2 Antagonist BRAF p53 MDM2 cobas 4800 BRAF V600E test AmpliChip p53 array cobas MDM2 expression assay Raf MEK ERK Cyclin D1 D1 Cell Cell cycle cycle progression and and proliferation I3K Forkhead p2 p2 77 Fas Fas LL AKT Bad Bad Survival AKT AKT Bcl-2 TSC TSC 1 TSC TSC 2 mtor mtor mtor rotein synthesis and and growth Tarceva RG7167 MEK Inh/CIF RG1273 ertuzumab RG3502 T-DM1 RG7321 I3K Inh RG7422 I3K Inh EGFR KRAS Her1, 2, 3 AREG, BTC IK3CA TheraScreen EGFR mutation test TheraScreen KRAS mutation test cobas 4800 HER Family expression assay CR IK3CA mutations FISH IK3CA copy number assay List not exhaustive 16
17 Key launches in 2010* Roche Investor event, AACC, July 26th rofessional Diagnostics Diabetes Care Molecular Diagnostics Applied Science Tissue Diagnostics cobas 8000 e 602 & c 702 modules (EU, AAC, LATAM) cobas 8000 c 701, c 502 and e 602 modules (US) cobas b 123 for bloodgas & electrolytes (EU) New immunoassays: 8 (US) 6 (EU) Accu-Chek Aviva Nano (US) Accu-Chek Mobile (AAC) Accu-Chek Combo (AAC) cobas TaqScreen DX blood screening test for B19 virus & HAV (EU) MRSA Test (US) CA/CTM CMV test (EU) GS Junior sequencing system (global) Next-generation ultra-high density NimbleGen microarrays (global) xcelligence RTCA HT instrument (global) Benchmark GX (EU, AAC) Molecular probes for Top2a and IGF-1R (EU) Discovery Ultra for IHC & ISH research (US EU) Diagnostics Division Outlook: Sales growth significantly above the market * Subject to appropriate regulatory approvals barring unforeseen events 17
18 We Innovate Healthcare 18
19 Q1 2010: Diagnostics Division sales Growth driven by EMEA and Asia acific CHF 2,518 m local sales growth North America 25% Diagnostics Division 9% Latin America 6% North America 5% 270 Asia acific 11% EMEA* 8% 118 Japan 4% Latin America 11% 1'352 EMEA 1 54% Asia acific 21% Japan 7% 1 Europe, Middle East and Africa 19
20 Q1 2010: Diagnostics Division local sales By Region and Business Area (vs. Q1 2009) Sales CHF m Global North Am. EMEA RoW % loc growth % loc growth % loc growth % loc growth rofessional Diag. 1, Diabetes Care Molecular Diagnostics Applied Science Tissue Diagnostics Diagnostics Division 2, ,
21 Diagnostics Division quarterly sales and local growth 1 Sales CHF m Q4 08 Q1 09 Q2 09 Q3 09 Q4 09 Q1 10 % loc % loc % loc % loc % loc % loc rofessional 1,139 9% 1,086 8% 1,152 9% 1,125 11% 1,190 8% 1,170 9% Diagnostics Diabetes 764-7% 679 4% 759 2% 720 7% % 708 6% Care Molecular 303 6% 294 7% 300 4% 288 3% 301 4% 294 2% Diagnostics Applied % 196 6% % % % % Science Tissue 115 n.a % % % % % Diagnostics DIA Division 2,544 9% 2,361 8% 2,541 7% 2,463 10% 2,690 10% 2,518 9% 1 versus same period of prior year 21
22 2010: Key planned product launches rofessional Diagnostics roduct Description Region Time cobas e 602 immunoassay module Module for the cobas 8000 modular analyser series for highvolume laboratories. Throughput: up to 170 tests/hour EU US Q2 Q3 cobas c 701 and cobas c 502 clinical chemistry modules Modules for the cobas 8000 modular analyser series. Throughput: up to 2,000 and 600 tests/hour, respectively US Q2 cobas c 702 advanced clinical chemistry module Module for the cobas 8000 modular analyser series. Features automated reagent loading, enabling consolidation of a broader test menu. Throughput: up to 1,900 tests/hour EU Q4 Immunochemistry menu Eight Elecsys immunoassays in the US; six in the EU Global Q1-Q4 HIV combi 27 min Improved combination assay for HIV 1 antigen (p24) and HIV antibodies, enabling more reliable early detection of infection with the human immunodeficiency virus EU Q4 cobas p 501 and cobas p 701 Automated post analytical sample storage and retrieval modules for bar-coded primary and secondary sample tubes US Q2 cobas b 123 OC system Benchtop multiparameter analyser for blood gas, electrolytes, COoximetry and metabolites. For use in critical care settings at the point of care lanned launches may be delayed or not occur as a result of adverse regulatory decisions or other factors. EU = European Union; EMEA = Europe, Middle East and Africa; AAC = Asia acific; LATAM = Latin America; US = United States. EU Q4 22
23 2010: Key planned product launches Diabetes Care roduct Description Region Time Accu-Chek Aviva Nano Sleeker versions of the Accu-Chek Aviva meter offering an enhanced feature set US H2 Accu-Chek Mobile Integrated lancing and blood glucose monitoring device employing a unique no strip technology that replaces single-use test strips with a continuous tape of 50 tests Additional EU markets Q1-Q4 AAC Q1 Accu-Chek Combo Interactive insulin delivery system combining an insulin pump (Accu-Chek Spirit Combo) and a blood glucose meter (Accu-Chek Aviva Combo) with broad data management capabilities; the meter also functions as a pump remote control Additional EU markets AAC Q1-Q4 Q1 lanned launches may be delayed or not occur as a result of adverse regulatory decisions or other factors. EU = European Union; EMEA = Europe, Middle East and Africa; AAC = Asia acific; LATAM = Latin America; US = United States. 23
24 2010: Key planned product launches Molecular Diagnostics roduct Description Region Time LightCycler MRSA Advanced Test Automated real-time CR-based test for methicillin-resistant Stapholococcus aureus US Q2 Cobas Amplirep/ Cobas TaqMan CMV Viral load monitoring test that will enable physicians to improve the management of cytomegalovirus (CMV) disease in solid organ transplant patients EU Q3 cobas TaqScreen DX Test Blood Screening test designed to simultaneously provide a quantitative result for parvovirus B19 virus and a qualitative result for hepatitis A virus EU Q3 Cobas Amplirep/ Cobas TaqMan HIV-1 v2 Second-generation test with a unique dual-target design enabling detection of two separate regions of the HIV-1 genome US Q4 Cobas Amplirep/ Cobas TaqMan HBV v2 Second generation fully automated HBV test with improved dynamic range requiring minimal serum and plasma sample volume US Q4 lanned launches may be delayed or not occur as a result of adverse regulatory decisions or other factors. EU = European Union; EMEA = Europe, Middle East and Africa; AAC = Asia acific; LATAM = Latin America; US = United States. 24
25 2010: Key planned product launches Applied Science roduct Description Region Time GS Junior System Economical benchtop next-generation DNA sequencing system for smaller laboratories Global Q2 NimbleGen CGX-6 multiplex arrays Microarrays for high-resolution analysis of chromosomal abnormalities; capable of analysing six samples simultaneously Global Q1 xcelligence RTCA HT instrument Automated high-throughput real-time cell analyses and screening Global Q1 SeqCap EZ Exome v.2 In-solution enrichment capture technology for targeted nextgeneration sequencing Global Q2 Arrays Next-generation ultra-high density NimbleGen microarrays Global H2 lanned launches may be delayed or not occur as a result of adverse regulatory decisions or other factors. EU = European Union; EMEA = Europe, Middle East and Africa; AAC = Asia acific; LATAM = Latin America; US = United States. 25
26 2010: Key planned product launches Tissue Diagnostics roduct Dual colour / dual hapten in situ hybridisation (ISH) kit anti-her2 neu (4B5) primary antibody and HER2 DNA probe BenchMark GX Molecular probes targeting the enzyme Top2a & the cell surface receptor IGF1R Discovery Ultra Description Enabling target gene detection and control on a single slide. For use with all molecular markers; specifically to support HER2 testing. For assessing likelihood of response to Herceptin treatment in both breast and gastric cancer patients Economical, low-volume advanced tissue staining platform that automates all slide processing steps from baking to staining For use as an aid in diagnosing and managing breast and lung cancer latform for immunohistochemistry and in situ hybridisation research, offering significant improvements in ease of use, workflow and flexibility Region EU EU EU, AAC EU US, EU AAC, Japan, LATAM lanned launches may be delayed or not occur as a result of adverse regulatory decisions or other factors. EU = European Union; EMEA = Europe, Middle East and Africa; AAC = Asia acific; LATAM = Latin America; US = United States. Time Q2 Q2 Q2 Q2-Q4 Q1, Q2 Q4 26
Diagnostics Division. Daniel O Day COO Roche Diagnostics
1 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates,
More informationDiagnostics Division. Daniel O Day COO Roche Diagnostics
1 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates,
More informationRoche Diagnostics. Daniel O Day COO Roche Diagnostics. Vontobel Summer Conference June 22, 2012
This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates,
More informationRoche Diagnostics Daniel O Day COO Roche Diagnostics. Société Générale - The Premium Review Conference, Paris December 2, 2011
This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates,
More informationRoche Lazard Capital Markets 7 th Annual Healthcare Conference. Thomas Kudsk Larsen, 17 November 2010
Roche Lazard Capital Markets 7 th Annual Healthcare Conference Thomas Kudsk Larsen, 17 November 2010 This presentation contains certain forward-looking statements. These forward-looking statements may
More informationInnovation and value creation. Severin Schwan, CEO Roche Group. Zurich, January 2015
Innovation and value creation Severin Schwan, CEO Roche Group Zurich, January 2015 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words
More informationScience, patient benefits and productivity
Science, patient benefits and productivity Alan Hippe, CFO Roche Group London, November 2017 This presentation contains certain forward-looking statements. These forward-looking statements may be identified
More informationJoachim Eberle Head of R&D, Roche Centralized Diagnostics
Workshop Roche Diagnostics and Biomarker Development Joachim Eberle Head of R&D, Roche Centralized Diagnostics Biomarkers and Roche Making a Diagnostics test Current rograms 2 Why is Roche interested in
More informationFocus and value creation
Focus and value creation Karl Mahler: Head IR Stefan Frings: Medical Affairs Director Germany London, November 2014 This presentation contains certain forward-looking statements. These forward-looking
More informationMolecular Probes Introducing 14 new probes
Molecular Probes Introducing 14 new probes Gene and Chromosome Probes Dual Colour ISH INFORM HER2 Dual ISH DNA Probe Cocktail Assay Product Part Number INFORM HER2 Dual ISH DNA Probe Cocktail 800-4422
More informationCowen Investor Conference March confidently live life with ease
Cowen Investor Conference March 2018 confidently live life with ease Forward-Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties that could
More informationJefferies Healthcare Conference. John Bishop Chairman & CEO June 2, 2014
Jefferies Healthcare Conference John Bishop Chairman & CEO June 2, 2014 1 Cepheid Cepheid Worldwide Market Growth by Segment Overall IVD sales are projected to grow at a 5.9% CAGR through 2017. Molecular
More informationRoche at a Glance An Introduction to our Company. February 2013
Roche at a Glance An Introduction to our Company February 2013 Basic facts at a glance Founded 1896 in Basel, Switzerland Founding families still hold majority stake Employing 80,000 people Currently active
More informationSlide 1. International Operations update. Mike Doustdar EVP International Operations. YASMIN FIEDLER, Germany Yasmin has type 1 diabetes
Slide 1 International Operations update Mike Doustdar EVP International Operations YASMIN FIEDLER, Germany Yasmin has type 1 diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with
More informationRoche Committed to innovation and profitable growth. Dr. Alan Hippe CFO Roche. Zurich, May 2011
Roche Committed to innovation and profitable growth Dr. Alan Hippe CFO Roche Zurich, May 2011 2 This presentation contains certain forward-looking statements. These forward-looking statements may be identified
More informationAVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer
FOR IMMEDIATE RELEASE AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer Study designed to build upon safety profile demonstrated
More informationDiagnostic test Suggested website label Description Hospitals available
Diagnostic test Suggested website label Description Hospitals available Abbott Molecular Inc, PATHVYSION HER-2 DNA Probe Kit (FISH) PathVysion kit A diagnostic tool used to determine whether a particular
More informationTransform genomic data into real-life results
CLINICAL SUMMARY Transform genomic data into real-life results Biomarker testing and targeted therapies can drive improved outcomes in clinical practice New FDA-Approved Broad Companion Diagnostic for
More informationRoche Group posts strong sales growth in the third quarter. Cancer medicines and clinical lab business drive Group performance
Media Release Basel, 16 October 2012 Roche Group posts strong sales growth in the third quarter Group sales rise 4% at CER 1 to 33.7 billion Swiss francs (+7% in Swiss francs) in the first nine months
More informationTranslating excellence in science into customer benefit. Pascal Soriot, Chief Operating Officer Roche Pharmaceuticals
Translating excellence in science into customer benefit Pascal Soriot, Chief Operating Officer Roche Pharmaceuticals Barclays Healthcare Conference, Miami March 16, 2011 This presentation contains certain
More informationDeveloping & Commercializing Targeted Small Molecule Drugs in Cancer
Developing & Commercializing Targeted Small Molecule Drugs in Cancer SAFE HARBOR STATEMENT 2 Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions
More informationPPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM
HEMATOLOGY ONCOLOGY PPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM COMMITTED TO ADVANCING DRUG DEVELOPMENT IN ONCOLOGY $ MARKETPLACE COMPLEXITIES increasingly competitive marketplace and rising cost pressures
More informationIdenix Pharmaceuticals Building a Leading Antiviral Franchise. Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston
Idenix Pharmaceuticals Building a Leading Antiviral Franchise Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston Safe Harbor This presentation includes forward-looking statements
More informationSlide 1. Investor presentation. London 5 February 2019
Slide Investor presentation London 5 February 209 Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this presentation
More informationDisruptive innovation in molecular diagnostics. Hilde Windels CEO Biocartis 25 March 2017
Disruptive innovation in molecular diagnostics Hilde Windels CEO Biocartis 25 March 2017 1 One of the key innovations in healthcare in the last decade PERSONALISED MEDICINE or HIGH PRECISION MEDICINE From
More informationInvesting in Innovation. John Bishop CEO & Chairman Baird Healthcare Conference 4 September, 2014
Investing in Innovation John Bishop CEO & Chairman Baird Healthcare Conference 4 September, 2014 1 Cepheid Cepheid Forward-Looking Statement During the course of this presentation, we may make projections
More informationARQ 087 Overview. FGFR Inhibitor. March 2017
ARQ 087 Overview FGFR Inhibitor March 2017 Safe Harbor This presentation and other statements by ArQule contain forward-looking statements within the meaning of the Private Securities Litigation Reform
More informationCorporate Update Simon Hubbert, CEO Bill Kullback, CFO June, 2015
(Nasdaq:EVAR) Corporate Update Simon Hubbert, CEO Bill Kullback, CFO June, 2015 Safe Harbor This presentation contains forward-looking statements as that term is defined in the Private Securities Litigation
More informationSales CHF millions As % of sales % change. In CHF Group sales 12,942 12,
Investor Update Basel, 27 April 2017 Roche reports a good start in 2017 Group sales increase 4% 1 at constant exchange rates and in Swiss francs Pharmaceuticals Division sales up 3%, driven mainly by Tecentriq
More informationTaiwan s Premier Biopharma and the future leader in Immuno-Oncology
1 Taiwan s Premier Biopharma and the future leader in Immuno-Oncology Safe Harbor Statement This presentation contains certain forwardlooking statements. These forward-looking statements may be identified
More informationTranslational Clinical Research, the Key to Personalised Healthcare in Practice
New Models of Collaborations with Academia to foster Translational Clinical Research, the Key to ersonalised Healthcare in ractice Exploratory Clinical Development World Europe Conference 2012 London,
More informationMATCHMAKING IN ONCOLOGY CHALLENGES AND COMBINATION STRATEGY FOR NOVEL TARGETED AGENTS
MATCHMAKING IN ONCOLOGY CHALLENGES AND COMBINATION STRATEGY FOR NOVEL TARGETED AGENTS DR. RACHEL E. LAING*, OLIVIER LESUEUR*, STAN HOPKINS AND DR. SEAN X. HU MAY 2012 Recent advances in oncology, such
More information33 rd Annual J.P. Morgan Healthcare Conference. January 2015
33 rd Annual J.P. Morgan Healthcare Conference January 2015 Forward-looking Statements This presentation contains forward-looking statements, which express the current beliefs and expectations of management.
More informationCanaccord Growth Conference August confidently live life with ease
Canaccord Growth Conference August 2018 confidently live life with ease Forward-Looking Statements This presentation contains forward-looking statements that are not purely historical regarding Senseonics
More informationRoche delivers good sales growth in the first nine months of 2016
Investor Update Basel, 20 October 2016 Roche delivers good sales growth in the first nine months of 2016 Group sales increase 4% 1 at constant exchange rates, 6% in Swiss francs Pharmaceuticals Division
More informationAnti-Infective Clinical Trials
Anti-Infective Clinical Trials The extensive clinical training and experience of our infectious disease staff places us in a unique position to fully appreciate the requirements of our clients conducting
More informationMyriad Genetics Corporate Presentation 06/13/2018
Myriad Genetics Corporate Presentation 06/13/2018 Copyright 2016 2018 Myriad Genetics, Inc., all rights reserved. www.myriad.com. 1 Forward Looking Statements Some of the information presented here today
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More informationBank of America Merrill Lynch HealthCare Conference Bayer HealthCare Dr. Jörg Reinhardt. September 14, 2011
Bank of America Merrill Lynch HealthCare Conference Bayer HealthCare Dr. Jörg Reinhardt Chairman of the Board of Management of Bayer HealthCare AG and Chairman of the Bayer HealthCare Executive Committee
More informationNestlé Investor Seminar 2008
Nestlé Investor Seminar 2008 Nestlé Nutrition update on Acquisitions Richard Laube CEO Nestlé Nutrition 1 Disclaimer This presentation contains forward looking statements which reflect Management s current
More informationUniversal Biosensors, Inc.
Universal Biosensors, Inc. ARBN 121 559 993 Buchan Three Tickers Presentation 18 th September 2013 1 Important Disclaimer This presentation is intended to provide a general outline only and is not intended
More information37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE
37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE January 2019 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationEnhancing Corporate Value
Goldman Sachs Twenty Sixth Annual Healthcare Conference Enhancing Corporate Value Eisai Co., Ltd. June 15, 2005 Please refer to the US Roadshow, June 2005 material in our WEB site for further information
More informationMyriad Genetics Corporate Presentation 6/4/13
Myriad Genetics Corporate Presentation 6/4/13 Forward Looking Statement Some of the information presented here today may contain projections or other forward-looking statements regarding future events
More informationDelivering on the Promise of Personalised Healthcare
Delivering on the Promise of Personalised Healthcare Dr John S Mills Diagnostic Team Director, Personalised Healthcare and Biomarkers Function, AstraZeneca, UK EBF 6 th Open Symposium, Barcelona, 20 Nov
More informationCommitted to innovation and growth
Committed to innovation and growth Roland Diggelmann, CEO Roche Diagnostics Paris, November 30, 2016 Q3 2016 Group results Diagnostics Business model & strategy Q3 2016 overview Investing in innovation
More informationSales CHF millions As % of sales % change. January - March CER CHF Group sales 13,583 12,
Investor Update Basel, 26 April 2018 Roche reports a strong start in 2018 Group sales increase 6% 1 at constant exchange rates and 5% in Swiss francs Pharmaceuticals Division sales up 7%, driven mainly
More informationPresentation to 2019 JP Morgan Healthcare Conference
For immediate release 10 January 2019 Presentation to 2019 JP Morgan Healthcare Conference Please find attached CSL Limited s presentation at the 2019 JP Morgan Healthcare Conference. For further information,
More informationCepheid The MDx Growth Leader. William Blair Growth Stock Conference June 12, 2012
Cepheid The MDx Growth Leader William Blair Growth Stock Conference June 12, 2012 Forward Looking Statement During the course of this presentation, we may make projections or other forward looking statements
More informationRoche Group s first-quarter 2011 sales on track for full-year targets positive results in seven key clinical trials
Media Release Basel, 14 April 2011 Roche Group s first-quarter 2011 sales on track for full-year targets positive results in seven key clinical trials Group Group sales stable in local currencies (-9%
More informationPutting ALK on the right growth trajectory
Putting ALK on the right growth trajectory Økonomisk Ugebrevs Kapitalmarkedseftermiddag 15. marts 2018 Per Plotnikof, VP Corporate Communications and IR Marts 2018 Allergy: a global disease with a large
More informationAVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC
FOR IMMEDIATE RELEASE AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC - Tivozanib is the First Agent to Demonstrate Greater than One Year
More informationSlide 1. Winning with GLP-1. Lars Fruergaard Jørgensen President and CEO. ALEXANDRE DE GREGORIO, Brazil Alexandre has type 2 diabetes
Slide 1 Lars Fruergaard Jørgensen President and CEO ALEXANDRE DE GREGORIO, Brazil Alexandre has type 2 diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the
More informationSlide 1. Investor presentation. Copenhagen 1 November 2018
Slide 1 Investor presentation Copenhagen 1 November 2018 Manato Shirley Ohara, Adelia Stewart diagnosed has type with 2 diabetes type 1 diabetes Kanagawa, New Orleans, Japan Louisiana, US Slide 2 Highlights
More informationOpportunities and Challenges in the Development of Companion Diagnostics
Opportunities and Challenges in the Development of Companion Diagnostics E. Patrick Groody, Ph.D. Divisional Vice President Research and Development Abbott Molecular Agenda Value of Personalized Medicine
More informationWe Innovate for Life John Bishop Chairman and Chief Executive Officer June 2016
We Innovate for Life John Bishop Chairman and Chief Executive Officer June 2016 1 Cepheid Forward-Looking Statement During the course of this presentation, we may make projections or other forward-looking
More informationInnovations in nucleic acid amplification technologies. Automated platforms for NAT. Microfluidics Digital PCR Innovations in nucleic acid microarrays
About the author Disclaimer EXECUTIVE SUMMARY Molecular diagnostic technologies Healthcare-associated infections Sexually transmitted HPVs HIV and hepatitis viruses Market outlook and forecasts Molecular
More informationVeriStrat Poor Patients Show Encouraging Overall Survival and Progression Free Survival Signal; Confirmatory Phase 2 Study Planned by Year-End
AVEO and Biodesix Announce Exploratory Analysis of VeriStrat-Selected Patients with Non-Small Cell Lung Cancer in Phase 2 Study of Ficlatuzumab Presented at ESMO 2014 Congress VeriStrat Poor Patients Show
More informationJanuary 2017 Investor Presentation. confidently live life with ease
January 2017 Investor Presentation confidently live life with ease Forward-Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties that could
More informationCorporate Presentation
Corporate Presentation January 2019 2018 Chembio. All Rights Reserved. # 2019 Chembio. All Rights Reserved. Page 1 Safe Harbor Statement Statements contained herein that are not historical facts are forward-looking
More informationPascal Soriot, Head of Strategic Marketing
Workshop Marketing a cancer drug Pascal Soriot, Head of Strategic Marketing Trends in the oncology market Europe/ RoW compared to US Marketing cancer drugs successfully Leveraging 1 st mover advantage
More informationA world leader in allergy immunotherapy
A world leader in allergy immunotherapy Investor Relations presentation June 2017 1 I Investor Relations presentation I June 2017 ALK: Towards redefining treatment of severe allergies The commercial leader
More informationInternational Operations overview and strategy. Maziar Mike Doustdar EVP International Operations. Slide 1
Slide 1 International Operations overview and strategy Maziar Mike Doustdar EVP International Operations KUALA LUMPUR Home of International Operations Business Area Southeast Asia Slide 2 Forward-looking
More informationMedia Contact: Ron Rogers Investor Contact: Scott Gleason (801) (801)
News Release Media Contact: Ron Rogers Investor Contact: Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Receives FDA Approval of BRACAnalysis CDx as Companion
More informationSurgical Pathology Lab of the Future. Thomas M. Grogan, M.D. Professor of Pathology, University of Arizona Founder, Ventana Medical Systems, Inc.
Surgical Pathology Lab of the Future Thomas M. Grogan, M.D. Professor of Pathology, University of Arizona Founder, Ventana Medical Systems, Inc. 28 April 2010 Objective Demonstrate how the next generation
More informationFitting the Treatment to the Patient Roche Personalized Healthcare. February 24, 2012
Fitting the Treatment to the Patient Roche Personalized Healthcare February 24, 2012 Roche Group Pharmaceuticals Roche Pharma Genentech Chugai Applied Science Molecular Professional Tissue Diabetes Care
More informationAdvance Your Genomic Research Using Targeted Resequencing with SeqCap EZ Library
Advance Your Genomic Research Using Targeted Resequencing with SeqCap EZ Library Marilou Wijdicks International Product Manager Research For Life Science Research Only. Not for Use in Diagnostic Procedures.
More informationRoche. Pascal Soriot COO Roche Pharmaceuticals
1 Roche Pascal Soriot COO Roche Pharmaceuticals 2 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates,
More informationThe clearest path to the most meaningful results. The cobas HPV Test delivers clinical value with workflow efficiencies every step of the way
The clearest path to the most meaningful results The cobas HPV Test delivers clinical value with workflow efficiencies every step of the way The cobas HPV Test KNOW THE RISK Help guide clinical decision
More informationCytomegalovirus (CMV) Infections - Pipeline Assessment and Market Forecasts to 2019
Reference Code: GDHC504PRT Publication Date: January 2013 Cytomegalovirus Infections: Key Metrics in Seven Major Pharmaceutical Markets 2012 Epidemiology* Prevalent population (CMV prevalent cases in general
More informationVisionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics
Dear VPEG Limited Partner, We hope this investor update finds you well. We're pleased to share with you an important update below on the following: Visionary Private Equity Group is Pleased to Announce
More informationQIAGEN Research & Development. Pipeline 2009/2010
QIAGEN Research & Development Pipeline 2009/2010 QIAGEN Analyst and Investor Day 2010 Dr. Joachim Schorr Senior Vice President Global Research & Development New York, February 11th, 2010 Agenda R&D @ QIAGEN
More informationAVENIO ctdna Analysis Kits The complete NGS liquid biopsy solution EMPOWER YOUR LAB
Analysis Kits The complete NGS liquid biopsy solution EMPOWER YOUR LAB Analysis Kits Next-generation performance in liquid biopsies 2 Accelerating clinical research From liquid biopsy to next-generation
More informationCompany Overview February 26, 2019
Company Overview February 26, 2019 SAFE HARBOR Cautionary Note Regarding Forward-Looking Statements Certain statements in this presentation constitute forward-looking statements, including, without limitation,
More informationJanuary 30, 2018 Dow Wilson President and Chief Executive Officer
Acquisition of SIRTeX January 30, 2018 Dow Wilson President and Chief Executive Officer This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward-Looking
More informationAVEO and Astellas Report Final Overall Survival Results from TIVO-1
AVEO and Astellas Report Final Overall Survival Results from TIVO-1 - Median Overall Survival of 28.8 Months Reported for Tivozanib in Patients with Advanced Kidney Cancer - CAMBRIDGE, Mass. and TOKYO,
More informationSlide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A
Slide 1 Financial update and closing remarks Jesper Brandgaard EVP and CFO RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A Slide 2 Forward-looking statements Novo Nordisk s reports filed with or
More informationNon-Invasive Array Based Screening for Cancer. Dr. Amit Kumar President and CEO CombiMatrix Corporation
Non-Invasive Array Based Screening for Cancer Dr. Amit Kumar President and CEO CombiMatrix Corporation www.combimatrix.com May 13, 2009 This presentation contains forward-looking statements within the
More informationWorkflow. Connecting the Pieces For Total Patient Care
Workflow Connecting the Pieces For Total Patient Care Biocare provides a full line of IHC and molecular pathology products for cancer and infectious disease diagnosis. From a full range of equipment: including
More informationPositioned for Growth
Positioned for Growth Annual Shareholders Meeting July 21, 2016 Paris Panayiotopoulos President and Chief Executive Officer David Sachs Non small cell lung cancer ARIAD clinical trial patient This presentation
More informationLeading the way in Integrated Diagnostics Solutions
Leading the way in Integrated Diagnostics Solutions Dr. Michael Heuer CEO Roche Diagnostics 10 January 2019 1 Diagnostics YTD Sep 2018 overview Strategy Newsflow & Innovation Outlook 2 YTD Sep 2018: Diagnostics
More informationPersonalised Healthcare. will it deliver? Bob Holland Head of Personalised Healthcare & Biomarkers Innovative Medicines AstraZeneca R&D
Personalised Healthcare x will it deliver? Bob Holland Head of Personalised Healthcare & Biomarkers Innovative Medicines AstraZeneca R&D Personalised Healthcare It is delivering! Bob Holland Head of Personalised
More informationBayer and Loxo Oncology to develop and commercialize two novel oncology therapies selectively targeting genetic drivers of cancer
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer and Loxo Oncology to develop and commercialize two novel oncology therapies
More informationJuly, ArQule, Inc.
July, 2012 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to clinical
More informationOncology Therapeutics without Compromise APRIL 2011
Oncology Therapeutics without Compromise APRIL 2011 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties, including among other
More informationPatrick J. Sullivan, President & CEO March 7, 2016 Raymond James 37 th Annual Institutional Conference
Patrick J. Sullivan, President & CEO March 7, 2016 Raymond James 37 th Annual Institutional Conference Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's
More informationLiquid Biopsies. Next Generation Cancer Molecular Diagnostics
Liquid Biopsies Next Generation Cancer Molecular Diagnostics Forward Looking Statements 2 Statements pertaining to future financial and/or operating results, future research, diagnostic tests and technology
More informationMerck Announces FDA Approval of KEYTRUDA. Provided to Investors as a Reference
Merck Announces FDA Approval of KEYTRUDA Provided to Investors as a Reference Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the safe harbor provisions
More informationNine months ended 30 September At CER* In CHF In USD Pharmaceuticals Division Excluding Tamiflu 24,397 24,096 28,395 27,587
Media Release Basel, 3 October 20 Roche posts solid sales performance in first nine months, achieves significant progress with personalised healthcare approaches Group sales rise 2% at CER (-2% in Swiss
More informationAdvanced Molecular Diagnostic Systems
Advanced Molecular Diagnostic Systems Company Annual General Meeting November 26th 2008 Allen Bollands, Chief Executive Officer Genera Biosystems: Technology for Molecular Diagnostics GBI s core business:
More informationGENETIC TESTING FOR TARGETED THERAPY FOR NON-SMALL CELL LUNG CANCER (NSCLC)
CANCER (NSCLC) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs are
More informationR&D AND INNOVATION. Francesco Colotta Senior Corporate VP and Chief Medical Officer
R&D AND INNOVATION Francesco Colotta Senior Corporate VP and Chief Medical Officer IN VITRO DIAGNOSTICS: BASICS DETECTION IN BIOLOGICAL FLUIDS... E.G. BLOOD, URINE, CSF, IN VITRO DIAGNOSTICS...OF A MOLECULE......
More informationThis is a licensed product of Ken Research and should not be copied
1 TABLE OF CONTENTS 1. The US Diabetes Care Devices Market Introduction 1.1. What is Diabetes and it s Types? 2. The US Diabetes Care Devices Market Size, 2007-2013 3. The US Diabetes Care Devices Market
More informationNGS IN ONCOLOGY: FDA S PERSPECTIVE
NGS IN ONCOLOGY: FDA S PERSPECTIVE ASQ Biomed/Biotech SIG Event April 26, 2018 Gaithersburg, MD You Li, Ph.D. Division of Molecular Genetics and Pathology Food and Drug Administration (FDA) Center for
More informationQuotient Limited. 36 th Annual JP Morgan Healthcare Conference. San Francisco, January 2018 THE FUTURE, MADE POSSIBLE
Quotient Limited 36 th Annual JP Morgan Healthcare Conference San Francisco, January 2018 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of
More informationQIAGEN Complete Solutions for Liquid Biopsy Molecular Testing
QIAGEN Complete Solutions for Liquid Biopsy Molecular Testing Christopher Swagell, PhD Market Development Manager, Advanced Molecular Pathology QIAGEN 1 Agenda QIAGEN Solid Tumor Testing and Liquid Biopsy
More informationDicerna Pharmaceuticals Overview. Delivering RNAi-Based Breakthrough Therapies
Pharmaceuticals Overview Delivering RNAi-Based Breakthrough Therapies Forward-Looking Statements This information may contain projections and other forward looking statements regarding future events, including
More informationStraumann s net revenues reach CHF 185 million in Q1, driven by continuing double-digit growth in America
Media release Straumann s net revenues reach CHF 185 million in Q1, driven by continuing double-digit growth in America Group net revenue rises 2% (l.c.) as double-digit increases across America offset
More informationFood & Beverages Food for a growing world
Food & Beverages Food for a growing world Rasmus von Gottberg, Vice President F&B Marketing, Novozymes Christel Thea Jørgensen, Vice President R&D, Novozymes Jeremy Bentham, Go to Market Director, Cargill
More information